Latest Mood stabilizers Stories
TSX: CLQ; U.S. OTCQX: CLQMF TORONTO, May 15, 2012 /CNW/ - Canada Lithium Corp. (TSX: CLQ) (OTCQX: CLQMF) announced today that it has signed a Memorandum of Understanding (MOU) with the Abitibiwinni First Nation of Pikogan and the Anishinabe First Nation of Lac-Simon communities near the Company's $207-million mine and processing plant currently under construction north of Val d'Or, Québec. The Company also announced it has received provincial approval for the location of its...
WASHINGTON, May 7, 2012 /PRNewswire/ -- In what may be the largest payment ever enforced involving off-label misuse of a single drug, law firm Grant & Eisenhofer, working with the U.S. Justice Department and several state Attorneys General, has reached a $1.6 billion settlement with Abbott Laboratories over its illegal marketing of antiepileptic medication Depakote to children and geriatric patients. The settlement was reached between Abbott (NYSE: ABT) and the Justice...
MAPLE GROVE, Minn., April 26, 2012 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. today announced the launch of http://www.seizureclusterstudy.com, an informational website for individuals diagnosed with partial or generalized epilepsy who experience seizure clusters and are interested in participating in an ongoing Phase III clinical trial. The study, ARTEMIS1 (Acute Rescue Therapy in Epilepsy with Midazolam Intranasal Spray) is designed to evaluate the efficacy and safety of...
Drug manufacturer deviates from appropriate comparator therapy specified by the G-BA The drug retigabine (trade name: Trobalt®) was approved in March 2011 as add-on therapy for adults with epileptic seizures. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products” (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether retigabine offers an added benefit compared with the present standard therapy....
Scientists have gained insight into why lithium salts are effective at treating bipolar disorder in what could lead to more targeted therapies with fewer side-effects. Bipolar disorder is characterised by alternating states of elevated mood, or mania, and depression. It affects between 1% and 3% of the general population. The extreme 'mood swings' in bipolar disorder have been strongly associated with disruptions in circadian rhythms – the 24-hourly rhythms controlled by our body...
In Jan 25th 2012, Abbott Laboratories (the company manufacturing Depakote) reported that 2011 selling, general and administrative expense report includes $1.5 billion of litigation reserves related to ongoing settlement discussions in the investigation by the U.S. Department of Justice, through the U.S. Attorney for the Western District of Virginia, related to Depakote. Depakote is a drug most commonly prescribed for psychiatric conditions like manic depressive disorder (bipolar disorder)...
CINCINNATI, Jan. 12, 2012 /PRNewswire/ -- Prasco® Laboratories announced today it has entered into an agreement with Shire (NASDAQ: SHPGY) for the distribution in the U.S. of the Authorized Generic version of Carbatrol® (Carbamazepine) Extended-Release Capsules in 100 mg, 200 mg and 300 mg strengths. Carbamazepine Extended-Release Capsules are AB-rated, therapeutically equivalent and substitutable for the brand Carbatrol®. The product will be distributed in the U.S. under the...
The Consumer Justice Foundation, whose Web site URL can be found at http://www.depakotebirthinjury.com, is a for-profit corporation staffed by a team of professional consumer advocates whose mission is to provide information for consumers concerning the potential dangers of certain prescription medications by way of free online educational resources. The CJF hereby alerts the public of the results of a survey concerning women who used hormonal birth control methods in conjunction with...
A lamotrigine/valproate treatment regimen significantly reduced seizure frequency A combination of two common drugs, lamotrigine and valproate, is more effective in treating difficult-to control epilepsy than other anti-epileptic regimens, according to a University of Washington report to be published online this week in Neurology, the journal of the American Academy of Neurology. More than 3 million Americans have epilepsy, and about one million of these have a difficult-to-treat form....
LAS VEGAS, Dec. 12, 2011 /PRNewswire/ -- First Liberty Power Corp. (OTCBB:FLPC) (the "Company") www.firstlibertypower.com would like to draw investor attention to recent positive news regarding the lithium sector. On Dec 6th, 2011, Bloomberg (Lithium, Cobalt Among Minerals Facing Chronic Shortage, PwC Says) reported "Global manufacturers may face a critical shortage of 14 raw materials over the next five years affecting industries including chemicals, aviation and renewable...
